Department of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Acta Neuropathol Commun. 2019 Oct 28;7(1):163. doi: 10.1186/s40478-019-0801-8.
In this multi-institutional study we compiled a retrospective cohort of 86 posterior fossa tumors having received the diagnosis of cerebellar glioblastoma (cGBM). All tumors were reviewed histologically and subjected to array-based methylation analysis followed by algorithm-based classification into distinct methylation classes (MCs). The single MC containing the largest proportion of 25 tumors diagnosed as cGBM was MC anaplastic astrocytoma with piloid features representing a recently-described molecular tumor entity not yet included in the WHO Classification of Tumours of the Central Nervous System (WHO classification). Twenty-nine tumors molecularly corresponded to either of 6 methylation subclasses subsumed in the MC family GBM IDH wildtype. Further we identified 6 tumors belonging to the MC diffuse midline glioma H3 K27 M mutant and 6 tumors allotted to the MC IDH mutant glioma subclass astrocytoma. Two tumors were classified as MC pilocytic astrocytoma of the posterior fossa, one as MC CNS high grade neuroepithelial tumor with BCOR alteration and one as MC control tissue, inflammatory tumor microenvironment. The methylation profiles of 16 tumors could not clearly be assigned to one distinct MC. In comparison to supratentorial localization, the MC GBM IDH wildtype subclass midline was overrepresented, whereas the MCs GBM IDH wildtype subclass mesenchymal and subclass RTK II were underrepresented in the cerebellum. Based on the integration of molecular and histological findings all tumors received an integrated diagnosis in line with the WHO classification 2016. In conclusion, cGBM does not represent a molecularly uniform tumor entity, but rather comprises different brain tumor entities with diverse prognosis and therapeutic options. Distinction of these molecular tumor classes requires molecular analysis. More than 30% of tumors diagnosed as cGBM belong to the recently described molecular entity of anaplastic astrocytoma with piloid features.
在这项多机构研究中,我们汇编了 86 例后颅窝肿瘤的回顾性队列,这些肿瘤均被诊断为小脑胶质母细胞瘤(cGBM)。所有肿瘤均经组织学复查,并进行基于阵列的甲基化分析,然后通过基于算法的分类归入不同的甲基化类别(MCs)。在被诊断为 cGBM 的 25 例肿瘤中,比例最大的单一 MC 为具有上皮样特征的间变性星形细胞瘤 MC,代表一种最近描述的分子肿瘤实体,尚未被纳入世界卫生组织中枢神经系统肿瘤分类(WHO 分类)。29 例肿瘤在分子上与包含在 MC GBM IDH 野生型家族中的 6 个甲基化亚类中的任何一个相对应。此外,我们鉴定出 6 例肿瘤属于 MC 弥漫性中线胶质瘤 H3 K27M 突变型,6 例肿瘤归入 MC IDH 突变型胶质瘤亚类星形细胞瘤。2 例肿瘤被归类为 MC 后颅窝毛细胞星形细胞瘤,1 例归类为 MC CNS 高级神经上皮肿瘤伴 BCOR 改变,1 例归类为 MC 对照组织,炎症性肿瘤微环境。16 例肿瘤的甲基化谱不能明确归入一个明确的 MC。与幕上定位相比,MC GBM IDH 野生型亚类中线过度表达,而小脑中 MC GBM IDH 野生型亚类间充质和亚类 RTK II 则表达不足。基于分子和组织学发现的综合分析,所有肿瘤均按照 2016 年 WHO 分类进行了综合诊断。总之,cGBM 不是一个分子上均匀的肿瘤实体,而是包含不同的脑肿瘤实体,具有不同的预后和治疗选择。区分这些分子肿瘤类别需要进行分子分析。超过 30%的被诊断为 cGBM 的肿瘤属于最近描述的具有上皮样特征的间变性星形细胞瘤的分子实体。